Posts

Posted on

Eagle Bulk Shipping Inc. to Participate in Bloomberg DryBulk Webinar

STAMFORD, Conn., March 29, 2021 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (NASDAQ: EGLE) (“Eagle Bulk”, “Eagle” or the “Company”), one of the world’s largest owner-operators within the Supramax / Ultramax drybulk segment, today announced that Gary Vogel, the Company’s Chief Executive Officer will participate in a Bloomberg Intelligence Webinar titled “Will Dry Bulk Finally Deliver?” on April 1, 2021 at 10:30 AM Eastern Time.

During the 1-hour webinar, which will be hosted by Lee Klaskow, Senior Analyst, Bloomberg Intelligence, Mr. Vogel will discuss the current dynamics in the drybulk shipping market, Eagle Bulk’s strategy and competitive positioning and the prospects for continued market strength throughout 2021 and beyond.

The webinar will be broadcast live and available for on-demand replay. It can accessed through a Bloomberg terminal or at no cost using Bloomberg’s website.

Please visit https://www.bloomberg.com/event-registration/?id=106179 to register for the webinar.

About Eagle Bulk Shipping Inc.

Eagle Bulk Shipping Inc. (“Eagle” or the “Company”) is a U.S. based fully integrated shipowner-operator providing global transportation solutions to a diverse group of customers including miners, producers, traders, and end users. Headquartered in Stamford, Connecticut, with offices in Singapore and Copenhagen, Denmark, Eagle focuses exclusively on the versatile mid-size drybulk vessel segment and owns one of the largest fleets of Supramax/Ultramax vessels in the world. The Company performs all management services in-house (including strategic, commercial, operational, technical and administrative) and employs an active management approach to fleet trading with the objective of optimizing revenue performance and maximizing earnings on a risk-managed basis. For further information, please visit our website: www.eagleships.com.

CONTACT

Company Contact:
Frank De Costanzo
Chief Financial Officer
Eagle Bulk Shipping Inc.
Tel. +1 203-276-8100
Email: [email protected]

Media:
Rose and Company
Tel. +1 212-359-2228



Posted on

TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQTM (umbralisib) , the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL). The U.S. FDA previously granted Fast Track designation to the combination of ublituximab and umbralisib (U2) for the treatment of adult patients with CLL and orphan drug designation for ublituximab in combination with umbralisib for the treatment of CLL. The BLA submission was based on the results of the UNITY-CLL trial, a global Phase 3 trial evaluating the combination of umbralisib plus ublituximab (U2) compared to obinutuzumab plus chlorambucil in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). 

Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, “The rapid completion of this BLA submission is a critical step forward in our mission to bring our first proprietary combination regimen to patients with both treatment naïve and relapsed or refractory chronic lymphocytic leukemia. The FDA has previously granted the U2 combination both fast track designation as well as orphan drug designation for patients with CLL and we look forward to continuing to work closely with the FDA with the goal of bringing this novel treatment regimen to patients as quickly as possible.” Mr. Weiss continued, “I want to thank the patients, their families and caregivers, as well as the research teams who participated in the UNITY-CLL trial, and also commend the TG team for their hard work to get this submission completed ahead of schedule.”

ABOUT UNITY-CLL PHASE 3 TRIAL
UNITY-CLL is a global Phase 3 randomized controlled clinical trial comparing the combination of ublituximab plus UKONIQ (umbralisib), or U2, to an active control arm of obinutuzumab plus chlorambucil in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). The trial randomized patients into four treatment arms: ublituximab single agent, UKONIQ single agent, ublituximab plus UKONIQ, and an active control arm of obinutuzumab plus chlorambucil. A prespecified interim analysis was conducted to assess the contribution of ublituximab and UKONIQ in the U2 combination arm and allowed for the termination of the single agent arms. Accordingly, the UNITY-CLL Phase 3 trial continued enrollment in a 1:1 ratio into the two combination arms: the investigational arm of U2 and the control arm of obinutuzumab plus chlorambucil. Approximately 420 subjects enrolled to the two combination arms and approximately 60% of patients were treatment-naïve and 40% were relapsed or refractory. The primary endpoint for this study was superior progression-free survival (PFS) for the U2 combination compared to the control arm to support the submission of the U2 combination in CLL. The trial met its primary endpoint and results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2020. The UNITY-CLL Phase 3 trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).

ABOUT CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia. It is estimated there will be more than 20,000 new cases of CLL diagnosed in the United States in 2020 and approximately 45,000 new cases globally in 2020.1,2 Although signs and symptoms of CLL may disappear for a period of time after initial treatment, the disease is considered incurable and many people will require additional treatment due to the return of malignant cells.

ABOUT FAST TRACK

Fast Track is a program designed to expedite the development and review of drugs that treat serious conditions and that demonstrate the potential to address an unmet medical need. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy that may be potentially better than available therapy.

A drug that receives Fast Track designation is eligible for more frequent interactions with the FDA, priority review if relevant criteria are met, and rolling submission of the Biologics License Application or New Drug Application.

ABOUT ORPHAN DRUG DESIGNATION
Orphan drug designation is granted by the FDA to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. Orphan drug designation provides certain incentives which may include tax credits towards the cost of clinical trials and prescription drug user fee waivers. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity.

ABOUT TG THERAPEUTICS, INC. 

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, UKONIQTM (umbralisib) received accelerated approval from the U.S. FDA for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and for the treatment of patients with chronic lymphocytic leukemia (CLL) as well as several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

UKONIQTM is a trademark of TG Therapeutics, Inc.

ABOUT UKONIQ™ (umbralisib)
UKONIQ is the first and only oral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon. PI3K-delta is known to play an important role in supporting cell proliferation and survival, cell differentiation, intercellular trafficking and immunity and is expressed in both normal and malignant B-cells. CK1-epsilon is a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies. 

UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

These indications are approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORANT SAFETY INFORMATION

Infections: Serious, including fatal, infections occurred in patients treated with UKONIQ. Grade 3 or higher infections occurred in 10% of 335 patients, with fatal infections occurring in <1% . The most frequent Grade ≥3 infections included pneumonia, sepsis, and urinary tract infection. Provide prophylaxis for Pneumocystis jirovecii pneumonia (PJP) and consider prophylactic antivirals during treatment with UKONIQ to prevent CMV infection, including CMV reactivation. Monitor for any new or worsening signs and symptoms of infection, including suspected PJP or CMV, during treatment with UKONIQ. For Grade 3 or 4 infection, withhold UKONIQ until infection has resolved. Resume UKONIQ at the same or a reduced dose. Withhold UKONIQ in patients with suspected PJP of any grade and permanently discontinue in patients with confirmed PJP. For clinical CMV infection or viremia, withhold UKONIQ until infection or viremia resolves. If UKONIQ is resumed, administer the same or reduced dose and monitor patients for CMV reactivation by PCR or antigen test at least monthly.

Neutropenia: Serious neutropenia occurred in patients treated with UKONIQ. Grade 3 neutropenia developed in 9% of 335 patients and Grade 4 neutropenia developed in 9%. Monitor neutrophil counts at least every 2 weeks for the first 2 months of UKONIQ and at least weekly in patients with neutrophil count <1 x 109/L (Grade 3-4) neutropenia during treatment with UKONIQ. Consider supportive care as appropriate. Withhold, reduce dose, or discontinue UKONIQ depending on the severity and persistence of neutropenia.

Diarrhea or Non-Infectious Colitis: Serious diarrhea or non-infectious colitis occurred in patients treated with UKONIQ. Any grade diarrhea or colitis occurred in 53% of 335 patients and Grade 3 occurred in 9%. For patients with severe diarrhea (Grade 3, i.e., > 6 stools per day over baseline) or abdominal pain, stool with mucus or blood, change in bowel habits, or peritoneal signs, withhold UKONIQ until resolved and provide supportive care with antidiarrheals or enteric acting steroids as appropriate. Upon resolution, resume UKONIQ at a reduced dose. For recurrent Grade 3 diarrhea or recurrent colitis of any grade, discontinue UKONIQ. Discontinue UKONIQ for life-threatening diarrhea or colitis.

Hepatotoxicity: Serious hepatotoxicity occurred in patients treated with UKONIQ. Grade 3 and 4 transaminase elevations (ALT and/or AST) occurred in 8% and <1%, respectively, in 335 patients. Monitor hepatic function at baseline and during treatment with UKONIQ. For ALT/AST greater than 5 to less than 20 times ULN, withhold UKONIQ until return to less than 3 times ULN, then resume at a reduced dose. For ALT/AST elevation greater than 20 times ULN, discontinue UKONIQ.

Severe Cutaneous Reactions: Severe cutaneous reactions, including a fatal case of exfoliative dermatitis, occurred in patients treated with UKONIQ. Grade 3 cutaneous reactions occurred in 2% of 335 patients and included exfoliative dermatitis, erythema, and rash (primarily maculo-papular). Monitor patients for new or worsening cutaneous reactions. Review all concomitant medications and discontinue any potentially contributing medications. Withhold UKONIQ for severe (Grade 3) cutaneous reactions until resolution. Monitor at least weekly until resolved. Upon resolution, resume UKONIQ at a reduced dose. Discontinue UKONIQ if severe cutaneous reaction does not improve, worsens, or recurs. Discontinue UKONIQ for life-threatening cutaneous reactions or SJS, TEN, or DRESS of any grade. Provide supportive care as appropriate.

Allergic Reactions Due to Inactive Ingredient FD&C Yellow No. 5: UKONIQ contains FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, frequently in patients who also have aspirin hypersensitivity.

Embryo-fetal Toxicity: Based on findings in animals and its mechanism of action, UKONIQ can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males with female partners of reproductive potential to use effective contraception during treatment and for at least one month after the last dose.

Serious adverse reactions occurred in 18% of 221 patients who received UKONIQ. Serious adverse reactions that occurred in ≥2% of patients were diarrhea-colitis (4%), pneumonia (3%), sepsis (2%), and urinary tract infection (2%). Permanent discontinuation of UKONIQ due to an adverse reaction occurred in 14% of patients. Dose reductions of UKONIQ due to an adverse reaction occurred in 11% of patients. Dosage interruptions of UKONIQ due to an adverse reaction occurred in 43% of patients.

The most commonadverse reactions (>15%), including laboratory abnormalities, in 221 patients who received UKONIQ were increased creatinine (79%), diarrhea-colitis (58%, 2%), fatigue (41%), nausea (38%), neutropenia (33%), ALT increase (33%), AST increase (32%), musculoskeletal pain (27%), anemia (27%), thrombocytopenia (26%), upper respiratory tract infection (21%), vomiting (21%), abdominal pain (19%), decreased appetite (19%), and rash (18%).

Lactation: Because of the potential for serious adverse reactions from umbralisib in the breastfed child, advise women not to breastfeed during treatment with UKONIQ and for at least one month after the last dose.

Please visit www.tgtherapeutics.com/prescribing-information/uspi-ukon for full Prescribing Information and Medication Guide.

1 Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL). National Cancer Institute Surveillance, Epidemiology, and End Results Program website. https://seer.cancer.gov/statfacts/html/clyl.html. Accessed October 26, 2020.
2 EpiCast Report: Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2025. Available at: https://store.globaldata.com/report/gdhcer164-17–epicast-report-chronic-lymphocytic-leukemia-epidemiology-forecast-to-2025/.


Cautionary Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to the BLA submission of ublituximab in combination with UKONIQTM (umbralisib), the clinical development of our product candidates, and anticipated milestones. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission, factors that could cause our actual results to differ materially are the following: risk that the FDA will not accept the BLA submission of ublituximab in combination with UKONIQ in patients with CLL, or if accepted, the risk that the FDA will not approve the BLA submission; the risk that fast track designation may not actually lead to a faster regulatory review or approval process; the risk that safety issues or trends will be observed in the UNITY-CLL study or in other studies that prevent approval of ublituximab in combination with UKONIQ; the risk that ublituximab in combination with UKONIQ, or any other product candidates, will not be commercially successful if approved; the risk that the differentiated tolerability profile for UKONIQ previously observed in clinical trials will not be reproduced in the UNITY-CLL trial or any other on-going studies; our ability to successfully and cost effectively complete preclinical and clinical trials; the uncertainties inherent in research and development; and the risk that the ongoing COVID-19 pandemic and associated government control measures have an adverse impact on our research and development plans or commercialization efforts. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in our other filings with the U.S. Securities and Exchange Commission.

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT:

Investor Relations

Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:

Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 6



Posted on

Arcosa, Inc. Announces Proposed Offering of $400 Million of Senior Notes

Arcosa, Inc. Announces Proposed Offering of $400 Million of Senior Notes

DALLAS–(BUSINESS WIRE)–
Arcosa, Inc. (NYSE: ACA) (“Arcosa”), a provider of infrastructure-related products and solutions, today announced that it intends to commence, subject to market conditions and other factors, a private offering of $400 million aggregate principal amount of senior notes due 2029 (the “Notes”).

Arcosa intends to use the net proceeds of the offering to fund the payment of the purchase price of the previously announced acquisition of StonePoint Ultimate Holding, LLC and affiliated entities (“StonePoint”), which is expected to close in April 2021, to repay any borrowings that may be outstanding under a new $150 million 364-day credit facility at the closing of the offering of the Notes, and to use any remaining net proceeds for general corporate purposes, which may include repayment in whole, or in part, of amounts outstanding under its existing revolving credit facility and other potential strategic investments. The closing of the offering is not conditioned upon the completion of the StonePoint acquisition. The Notes will be senior unsecured obligations of Arcosa and will initially be guaranteed on a senior unsecured basis by each of Arcosa’s domestic subsidiaries that is a guarantor under its existing senior credit facility.

The Notes and the related guarantees are being offered and sold only to persons reasonably believed to be “qualified institutional buyers” in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to certain non-U.S. persons in compliance with Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered for sale under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, the Notes or any other securities, and shall not constitute an offer to sell, solicitation of an offer to buy, or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offers of the Notes will be made only by means of a private offering memorandum.

About Arcosa

Arcosa, Inc. (NYSE: ACA), headquartered in Dallas, Texas, is a provider of infrastructure-related products and solutions with leading positions in construction, engineered structures, and transportation markets. Arcosa reports its financial results in three principal business segments: Construction Products, Engineered Structures, and Transportation Products. For more information, visit www.arcosa.com.

Some statements in this release, which are not historical facts, are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about Arcosa’s estimates, expectations, beliefs, intentions or strategies for the future. Arcosa uses the words “anticipates,” “assumes,” “believes,” “estimates,” “expects,” “intends,” “forecasts,” “may,” “will,” “should,” “guidance,” “outlook,” “strategy,” and similar expressions to identify these forward-looking statements. Forward-looking statements speak only as of the date of this release, and Arcosa expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein, except as required by federal securities laws. Forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results to differ materially from historical experience or our present expectations, including but not limited to assumptions, risks and uncertainties regarding the completion of the StonePoint acquisition; the impact of the COVID-19 pandemic on Arcosa’s customer demand for Arcosa’s products and services, Arcosa’s supply chain, Arcosa’s employees’ ability to work because of COVID-19 related illness, the health and safety of our employees, the effect of governmental regulations imposed in response to the COVID-19 pandemic; assumptions, risks and uncertainties regarding achievement of the expected benefits of Arcosa’s spin-off from Trinity; tax treatment of the spin-off; market conditions and customer demand for Arcosa’s business products and services; the cyclical nature of, and seasonal or weather impact on, the industries in which Arcosa competes; competition and other competitive factors; governmental and regulatory factors; changing technologies; availability of growth opportunities; market recovery; ability to improve margins; risks and uncertainties related to the capital markets generally; whether Arcosa will consummate the offering; the anticipated terms of the Notes and the anticipated use of proceeds; and Arcosa’s ability to execute its long-term strategy, and such forward-looking statements are not guarantees of future performance. For further discussion of such risks and uncertainties, see “Risk Factors” and the “Forward-Looking Statements” section of “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Arcosa’s Form 10-K for the year-ended December 31, 2020, as may be revised and updated by Arcosa’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

INVESTORS

Scott C. Beasley

Chief Financial Officer

Gail M. Peck

SVP, Finance & Treasurer

T 972.942.6500

[email protected]

David Gold

ADVISIRY Partners

T 212.661.2220

[email protected]

MEDIA

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Construction & Property Other Manufacturing Other Transport Engineering Logistics/Supply Chain Management Other Construction & Property Transport Manufacturing

MEDIA:

Posted on

Nomad Foods to Acquire Fortenova’s Frozen Food Business Group

 Nomad Foods to Acquire Fortenova’s Frozen Food Business Group

 Further reinforces Nomad’s European frozen food leadership with multiple levers for value creation & synergies

Market leading brands Ledo and Frikom provide entry into attractive Central & Eastern European markets

Expect 2021 combined Adjusted EPS above $2.00 per share on an annualized basis

Expected to be high-single digit % accretive to Adjusted EPS in Year 1, before synergies

FELTHAM, England–(BUSINESS WIRE)–
Nomad Foods Limited (NYSE: NOMD) announced today that it has entered into an agreement to acquire Fortenova Group’s Frozen Food Business Group (FFBG) for aggregate consideration of approximately €615 million on a debt-free, cash free basis.

FFBG is a leading European frozen food portfolio operating in attractive markets new to Nomad, including Croatia, Serbia and Bosnia & Herzegovina, Hungary, Slovenia, Kosovo, North Macedonia and Montenegro. Its two anchor brands, Ledo and Frikom, have unparalleled consumer awareness and #1 market share in many of these markets and offer a broad range of frozen food products including fish, fruits, vegetables, ready meals, pastry and ice cream.

Stéfan Descheemaeker, Nomad Foods’ Chief Executive Officer, stated, “The acquisition of FFBG reinforces Nomad’s European frozen food leadership while strategically expanding our portfolio into attractive new markets and creating an exciting new category adjacency in ice cream. Like Birds Eye, Findus and iglo, Ledo and Frikom are institutions in their respective markets with strong consumer awareness and #1 market share. Similar to Nomad, FFBG is singularly focused on frozen food, a fantastic category that is aligned with consumer trends including convenience and sustainability. We plan to leverage our combined pan-European scale, commercial expertise and passion for frozen food while harnessing the unique local characteristics and traditions of FFBG’s brands.”

Noam Gottesman, Nomad Foods’ Co-Chairman and Founder, commented, “We are delighted to announce this acquisition, which is consistent with our growth strategy and builds on our five-year track record of top-tier shareholder value creation. This transaction provides a natural extension to our existing business and creates a new platform for future expansion within Central and Eastern Europe. It also introduces us to ice cream, an exciting new category which opens new potential avenues for growth. Following the acquisition, our annual revenue will approach €3 billion, nearly doubling the revenue base of Iglo Group, our initial anchor acquisition in 2015. We are proud of what we have accomplished so far, and we believe there is much more to come. We look forward to welcoming the FFBG team into the Nomad family.”

This acquisition is highly strategic and financially impactful for Nomad:

  • Expansion into New and Attractive Central & Eastern European markets. FFBG is the leading frozen food company in several European markets, including Croatia, Serbia and Bosnia & Herzegovina, Hungary, Slovenia, Kosovo, North Macedonia and Montenegro. These are large and attractive markets where consumer demand for frozen food is developing, which creates a compelling long-term growth opportunity. Management expects FFBG’s organic growth to be in the mid-single digits range, double the 2-3% organic growth profile of Nomad’s existing business. The acquisition of FFBG will expand Nomad’s portfolio into this attractive region while creating a strategic platform for further expansion within Central & Eastern Europe.
  • Ledo and Frikom Brands are the Clear Frozen Food Leaders. FFBG’s core brands, Ledo and Frikom, have strong consumer awareness and #1 market share in many of their respective markets. Ledo and Frikom share many of the same characteristics as Nomad’s existing power brands Birds Eye, Findus and iglo which are sold across Western Europe. As a result, FFBG’s brands stand to benefit from the commercial playbook that has enabled Nomad’s profitable growth to-date, including portfolio management, innovation, R&D, net revenue management, and media efficiency.
  • Entry into Ice Cream Creates an Exciting New Product Adjacency and is Seasonally Complementary to Nomad’s Core Savory Portfolio. Ice Cream, a new category to Nomad, represents approximately 50% of FFBG’s revenues and will account for approximately 5% of the combined annual revenue base. This profitable category is highly synergistic with savory frozen food in FFBG’s core markets and provides Nomad with new category expertise. Further, the seasonal concentration of ice cream profits in the summer months will be seasonally complementary to Nomad’s existing frozen savory portfolio, which is skewed to the winter months, namely Q1 and Q4.
  • Multiple Levers for Value Creation and Synergies. Management sees an opportunity to expand FFBG’s Adjusted EBITDA base by approximately 50%, partly driven by an estimated €15 million of annual run-rate synergies by 2024 through a combination of scale, operational excellence, commercial optimization, and expense management.
  • Anticipate High-Single Digit % Accretion in Year 1 with 2021 Combined Annual Adjusted EPS Above $2.00 Per Share. FFBG is expected to generate annual revenue and Adjusted EBITDA of €279 million and €53 million, respectively in 2021. Management anticipates the transaction to enhance Nomad’s long-term organic revenue and Adjusted EBITDA growth profiles while also being high-single digit % accretive to Adjusted EPS in Year 1, before synergies. Combined 2021 Adjusted EPS is expected to exceed $2.00 per share on an annualized basis.
  • Firmly Aligned with Management’s Disciplined Acquisition Criteria. The acquisition of FFBG aligns with management’s articulated strategy of expanding Nomad’s frozen food portfolio into new geographies, categories and channels. FFBG has a market leading position, an attractive growth profile and generates strong cash flow consistent with Nomad’s investment criteria. Furthermore, the implied transaction multiple of under 10x EBITDA, including run-rate synergies, reflects the Company’s commitment to valuation discipline.

Management intends to update guidance on the combined entities for the current year upon closing of the transaction, which is expected to be completed during the third quarter of 2021 subject to approval of a majority of the depositary receipt holders of the ultimate parent of the seller and satisfactions of other certain closing conditions. The purchase price is expected to be funded through cash on hand and debt. The transaction has been unanimously approved by the board of directors of the seller which consists of representatives of more than a majority of the depositary receipt holders of the ultimate parent of the seller.

Morgan Stanley acted as financial advisor and Norton Rose Fulbright, Divjak Topic Bahtijarevic & Krka Law Firm and BDK Advokati are acting as legal advisors to Nomad Foods on the transaction.

Conference Call and Webcast

The Company will host a conference call with members of the executive management team to discuss the transaction today, Monday, March 29, 2021 at 1:30 p.m. BST (8:30 a.m. Eastern Daylight Time). Investors interested in participating in the live call can dial +1-877-451-6152 from North America. International callers can dial +1-201-389-0879.

In addition, the call will be broadcast live over the Internet hosted at the “Investor Relations” section of the Company’s website at http://www.nomadfoods.com. The webcast will be archived for 30 days. A replay of the conference call will be available on the Company website for two weeks following the event and can be accessed by listeners in North America by dialing +1-844-512-2921 and by international listeners by dialing +1-412-317-6671; the replay pin number is 13718228.

About Nomad Foods

Nomad Foods (NYSE: NOMD) is Europe’s leading frozen foods company. The company’s portfolio of iconic brands, which includes Birds Eye, Findus, iglo, Aunt Bessie’s and Goodfella’s, have been a part of consumers’ meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com.

Forward-Looking Statements and Disclaimers

Certain statements in this announcement are forward-looking statements which are based on the Company’s expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts, including expectations regarding: (i) the Company’s ability to create shareholder value through a combination of organic growth and the accretive deployment of capital; (ii) the Company’s ability to replicate its growth model, expand its geographic reach within Central and Eastern Europe and extend its product offering and brand family; (iii) the success of the Company’s strategic initiatives and growth strategy, including the impact of the acquisition on long-term value creation and long-term growth; (iv) the organic growth of FFBG; (v) the future operating and financial performance of the Company, including the expected annual revenue and adjusted EBITDA of FFBG in 2021; (vi) achievement of run-rate synergies through a combination of scale, operational excellence, commercial optimization and expense management; and (vii) the funding and timing of closing of the acquisition. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including (i) the operating and financial performance of the Company following the acquisition is worse than anticipated; (ii) the Company is not able to achieve the planned synergies; (iii) economic conditions, competition and other risks that may affect the Company’s future performance; and (iv) the other risks and uncertainties disclosed in the Company’s public filings and any other public disclosures by the Company. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release contains forward-looking non-IFRS financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission including combined adjusted EBITDA and combined revenues. The Company uses certain non-IFRS financial measures that are included in this press release and the additional financial information both in explaining its results to shareholders and the investment community and in its internal evaluation and management of its businesses. The Company does not provide reconciliations of forward-looking non-U.S. IFRS financial information due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, the amount of which, based on historical experience, could be significant.

Investor Relations Contacts

Taposh Bari, CFA

Nomad Foods Limited

+1-718-290-7950

John Mills

ICR, Partner

+1-646-277-1254

Media Contact

Felipe Ucros

Gladstone Place Partners

+1-212-230-5930

RELATED LINKS

http://www.nomadfoods.com

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Retail Supermarket Food/Beverage

MEDIA:

Posted on

ADDING MULTIMEDIA TrueBlue’s Andrea Brogger Named One of the Most Influential HR Leaders in U.S.

ADDING MULTIMEDIA TrueBlue’s Andrea Brogger Named One of the Most Influential HR Leaders in U.S.

Workforce solution leader’s chief people officer recognized for spearheading the company’s human resources strategy

TACOMA, Wash.–(BUSINESS WIRE)–
Today, TrueBlue, The People Company®, announced that its Chief People Officer, Andrea Brogger, has been named one of the 10 most influential HR leaders in the U.S. by Insights Success magazine. In being named to the list, Brogger was cited for her innovation in HR, her employee engagement efforts, and her focus on connectivity between people strategy and business results.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005214/en/

TrueBlue's Chief People Officer, Andrea Brogger, has been named one of the 10 most influential HR leaders in the U.S. (Graphic: Business Wire)

TrueBlue’s Chief People Officer, Andrea Brogger, has been named one of the 10 most influential HR leaders in the U.S. (Graphic: Business Wire)

In recognition of HR’s vital role in business success, the annual list identifies those HR leaders who have helped organizations and businesses make revolutionary leaps in human resource management.

“With people at the heart of our mission, ensuring that TrueBlue is a place where all people can advance and thrive is essential. We are committed to making TrueBlue an exceptional place to work and Andrea’s work is a big part of that,” said Patrick Beharelle, TrueBlue’s CEO. “It is great to see this recognition of our HR strategy as we strive to connect people and work and to be a force for good in the communities that we serve.”

Brogger has been with TrueBlue since 2011. She is responsible for empowering TrueBlue’s 5,100 global employees to achieve the company’s mission of connecting people and work. Brogger was named the company’s chief people officer in 2020. Prior to her current role, she served as the vice president of global talent and culture at TrueBlue, where she spearheaded multiple employee engagement programs for the company’s global workforce, with a particular focus on teams working remotely.

Before joining TrueBlue, Brogger most recently worked for Microsoft. She holds a master’s degree in business administration and an executive master’s degree in human resources management from Cornell University.

About TrueBlue

TrueBlue (NYSE: TBI), The People Company®, is a leading provider of specialized workforce solutions that help clients achieve business growth and improve productivity. In 2020, TrueBlue connected approximately 490,000 people with work. Its PeopleReady segment offers on-demand, industrial staffing, PeopleManagement offers contingent, on-site industrial staffing and commercial driver services, and PeopleScout offers recruitment process outsourcing (RPO) and managed service provider (MSP) solutions to a wide variety of industries. Learn more at www.trueblue.com.

About Insights Success

Insights Success is the Best Business Magazine across the globe for enterprises. Being a progress-driven platform, it focuses distinctively on emerging as well as leading companies, their reformative style of conducting business and ways of delivering effective and collaborative solutions to strengthen market share. Here, we talk about leaders’ viewpoints & ideas, latest products/services, etc. Insights Success magazine reaches out to all the ‘C’ Level professional, VPs, Consultants, VCs, Managers, and HRs of various industries. Learn more at www.insightssuccess.com.

David Irwin

TrueBlue Communications Director

[email protected]

630-453-1120

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Professional Services Human Resources

MEDIA:

Logo
Logo
Photo
Photo
TrueBlue’s Chief People Officer, Andrea Brogger, has been named one of the 10 most influential HR leaders in the U.S. (Graphic: Business Wire)
Posted on

Building on an Existing Track Record of Health and Safety Excellence, Ameresco Expands Programs

Building on an Existing Track Record of Health and Safety Excellence, Ameresco Expands Programs

Ameresco launches Global Safety Ambassadors Program highlighting its continued focus on safety across all project sites

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Ameresco, Inc., (NYSE: AMRC), a leading cleantech integrator specializing in energy efficiency and renewable energy, today announced the expansion of its health and safety initiatives to include a Global Safety Ambassadors program. The company’s emphasis on safety excellence has instilled a relentless focus on the health and safety of their employees, contractors, customers, and communities.

The company maintains a long history of established safety practices and protocols at construction sites and operational assets, with individuals holding a variety of current OSHA, Environmental, and USACE EM 385-1-1 certifications. Due to the complexity of on-site projects where employee safety is of critical importance, Ameresco has historically utilized an integrated safety management approach to ensure that safety is incorporated in the planning and execution of all work, along with a master safety plan that functions as a basis for site specific plans at each of their worksites.

The newly established Global Safety Ambassadors committee expands upon the previously instituted safety programs and includes two representatives – one management and one non-management level – from each of Ameresco’s business units. By establishing a concentrated committee dedicated to promoting and fostering employee and company safety, Ameresco’s Global Safety Ambassadors will solicit input and evaluate program performance to provide recommendations to senior and executive level management for continued overall process improvements. The program’s objectives include reducing the incidence of injury and illness throughout the company, improving overall safety in the work environment, maintaining lines of communication with all employees, and protecting the company’s assets.

In 2021, Ameresco executive vice president and director, David Anderson will serve as the Global Safety Ambassadors’ executive representative, acting as a liaison between the program and the management team. Ken Gross, Ameresco’s senior vice president of safety, quality and risk management, will act as committee chair, developing and leading the Global Safety Ambassadors program with his team located across the company.

“Having worked in the energy industry for over 35 years, I know there is nothing more important than a strong organizational foundation that prioritizes the health and safety of our employees, contractors, partners and communities,” said David Anderson, executive vice president and director at Ameresco. “Whether we are supporting educational campus operations, municipal buildings, commercial or industrial operations, or mission critical military operations, the health and safety of those around us are always front of mind. I believe the establishment and implementation of the Global Safety Ambassadors’ program will prove to be a vital component of our health and safety, quality assurance and risk management process.”

As a company dedicated to “doing well by doing good,” the Ameresco Global Safety Ambassadors program prioritizes an investment in the health and wellness of its employees. It also reflects one of the company’s core values, as highlighted in its inaugural 2020 ESG report, which aims to foster a workplace that protects and safeguards the lives of its employees first and foremost.

“Expanding our current safety program as we continue to grow is central to our vision of adding value to not only improve the lives of the communities we serve, but to enhance the quality of life for our employees,” said Ken Gross, committee chairman of Ameresco’s Global Safety Ambassadors program and senior vice president of safety, quality and risk management. “The Global Safety Ambassadors program is reflective of our responsibility to identify, investigate and eliminate any potential hazards in the workplace and encourage the active participation of all in safety processes.”

To learn more about Ameresco’s environmental, social and corporate governance initiatives, view its 2020 inaugural ESG report, found here https://www.ameresco.com/esg/.

About Ameresco, Inc.

Founded in 2000, Ameresco, Inc. (NYSE:AMRC) is a leading cleantech integrator and renewable energy asset developer, owner and operator. Our comprehensive portfolio includes energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions delivered to clients throughout North America and the United Kingdom. Ameresco’s sustainability services in support of clients’ pursuit of Net Zero include upgrades to a facility’s energy infrastructure and the development, construction, and operation of distributed energy resources. Ameresco has successfully completed energy saving, environmentally responsible projects with Federal, state and local governments, healthcare and educational institutions, housing authorities, and commercial and industrial customers. With its corporate headquarters in Framingham, MA, Ameresco has more than 1,000 employees providing local expertise in the United States, Canada, and the United Kingdom. For more information, visit www.ameresco.com.

Ameresco: Leila Dillon, 508-661-2264, [email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Utilities Human Resources Environment Alternative Energy General Health Health Energy Professional Services

MEDIA:

Logo
Logo
Posted on

Keats Infill Drilling Returns 37.2 g/t Au over 6.45m and 17.9 g/t Au over 8.45m

PR Newswire

VANCOUVER, BC, March 29, 2021 /PRNewswire/ – New Found Gold Corp. (“New Found” or the “Company“) (TSXV: NFG) (OTC: NFGFF) is pleased to announce assay results from an additional six holes drilled at the Keats Zone (“Keats“). These holes were drilled as part of the Company’s ongoing 200,000m diamond drill program at its 100%-owned Queensway Project (“Queensway“), located on the Trans-Canada Highway 15 km west of Gander, Newfoundland. 

Highlights

  • Highlights include:


Hole No.


From (m)


To (m)


Interval (m)*


Au (g/t)


NFGC-21-78


113.20


115.50


2.30


18.22


NFGC-21-86


141.95


150.00


8.05


5.6


NFGC-21-87


4.70


9.35


4.65


27.8


And


20.45


30.70


10.25


2.5


NFGC-21-97


174.95


181.40


6.45


37.1


NFGC-21-101


180.85


189.30


8.45


17.9

*Note that the host structures are interpreted to be steeply dipping and true widths are estimated to be 70% to 80% of reported intervals. Intervals are calculated at a 1 g/t Au cut-off grade; grades have not been capped in the averaging.

  • The intervals of 37.2 g/t Au over 6.45m and 17.9 g/t Au over 8.45m in drill holes NFGC-21-97 and NFGC 21-101 provide further confirmation of the continuity of the Keats high grade zone in the down-plunge direction (Figure 1).
  • Drill hole NFGC-21-87 returned 27.8 g/t Au over 4.65 m starting at 4.7m down-hole depth plus 2.51 g/t Au over 10.3 m starting at 20.5m down-hole depth, providing further confirmation of high-grade gold at bedrock surface at the north end of Keats.

Greg Matheson, P.Geo., COO of New Found, stated: “These results are significant in that they provide confirmation of the continuity of high-grade gold mineralization between our deeper results down plunge including the recently released 61.8 g/t Au over 13.65m in NFGC-21-118 and the more closely spaced drilled near-surface, high-grade results up-plunge (see Figure 1). Additional results in this area roughly centered around fence line 4700N are anticipated shortly. Current drilling at Keats is focused on extending the high-grade zone down plunge, providing further definition of the near surface, high-grade mineralization, and testing additional zones of high-grade mineralization including in the footwall veining.“

Highlights – Keats Main Zone Drill Intervals


Hole


Interval


Au


Hole


Interval


Au


Hole


Interval


Au


Hole


Interval


Au


(m)


(g/t)


(m)


(g/t)


(m)


(g/t)


(m)


(g/t)


19-01


19.0


92.9


20-32


13.1


45.3


20-45


13.8


28.4


21-79


7.9


22.7


20-18


7.9


24.1


20-34


2.4


29.3


And


3.3


20.6


21-80


39.1


25.8


20-19


18.9


31.2


20-37


10.3


25.0


And


2.0


17.1


  And


2.3


41.6


20-21


18.4


15.8


20-38


5.8


19.8


20-46


2.9


13.7


21-87


4.7


27.8


20-23


41.4


22.3


20-40A


7.3


19.3


21-52


2.1


136.7


21-90


3.9


24.5


20-26


6.9


44.5


20-41


10.4


22.5


And


14.1


31.5


21-97


6.5


37.1


20-28


4.1


40.1


   And


15.9


31.4


And


5.6


13.7


21-101


8.5


17.9


20-29


16.9


25.0


20-43


18.2


10.0


20-56


32.3


6.2


21-104


11.4


29.1


20-30


6.1


10.3


21-78


2.3


18.2


21-118


13.7


61.8

Drillhole Details

Table 2: Summary of results reported in this news release.


Hole No.


From (m)


To (m)


Interval (m)*


Au (g/t)


Zone


NFGC-21-65


170.00


172.90


2.90


1.04


Keats Main


NFGC-21-78


102.00


105.70


3.70


2.43


Keats Main


And


113.20


115.50


2.30


18.2


NFGC-21-86


141.95


150.00


8.05


5.65


Keats Main


And


171.90


174.25


2.35


1.09


NFGC-21-87


4.70


9.35


4.65


27.8


Keats Main


And


20.45


30.70


10.25


2.51


And


79.00


81.00


2.00


2.03


NFGC-21-97


135.00


137.65


2.65


1.31


Keats HW


And


153.65


156.00


2.35


1.04


Keats Main


And


162.65


167.00


4.35


1.21


And


174.95


181.40


6.45


37.2


NFGC-21-101


180.85


189.30


8.45


17.9


Keats Main

*Note that the host structures are interpreted to be steeply dipping and true widths are estimated to be 70% to 80% of reported intervals. Intervals are calculated at a 1 g/t Au cut-off grade; grades have not been capped in the averaging.

Table 3: Location details of drill holes reported on in this news release.


Hole No.


Azimuth (°)


Dip (°)


Length (m)


UTM E


UTM N


NFGC-21-65


300


-45


266


658335


5427512


NFGC-21-78


300


-45


168


658183


5427426


NFGC-21-86


300


-45


231


658209


5427397


NFGC-21-87


300


-45


125


658218


5427535


NFGC-21-97


300


-45


225


658195


5427347


NFGC-21-101


300


-45


221


658206


5427341

Sampling, Sub-sampling and Laboratory 
True widths of the intercepts reported in this press release have yet to be determined but are estimated to be 70% to 80% of reported core lengths. Assays are uncut, and calculated intervals are reported over a minimum length of 2 meters using a lower cut-off of 1.0 g/t Au. All HQ split core assays reported were obtained by either complete sample metallic screen/fire assay or standard 30-gram fire-assaying with ICP finish at ALS Minerals in Vancouver, British Columbia, or by entire sample screened metallic screen fire assay at Eastern Analytical in Springdale, Newfoundland. The complete sample metallic screen assay method is selected by the geologist when samples contain coarse gold or any samples displaying gold initial fire assay values greater than 1.0 g/t Au. Drill program design, Quality Assurance/Quality Control and interpretation of results is performed by qualified persons employing a Quality Assurance/Quality Control program consistent with National Instrument 43-101 and industry best practices. Standards and blanks are included with every 20 samples for Quality Assurance/Quality Control purposes by the Company as well as the lab. Approximately 5% of sample pulps are sent to secondary laboratories for check assays.

Qualified Person
The technical content disclosed in this press release was reviewed and approved by Greg Matheson, P. Geo., Chief Operating Officer, and a Qualified Person as defined under National Instrument 43-101. Mr. Matheson consents to the publication of this news release dated March 29, 2021 by New Found. Mr. Matheson certifies that this news release fairly and accurately represents the information for which he is responsible.

About New Found Gold Corp.
New Found holds a 100% interest in the Queensway Project, located 15 km west of Gander, Newfoundland, and just 18 km from Gander International Airport. The project is intersected by the Trans-Canada Highway and has logging roads crosscutting the project, high voltage electric power lines running through the project area, and easy access to a highly skilled workforce. The Company is currently undertaking a 200,000-m drill program at Queensway, with a planned increase from the current six drill rigs to eight drill rigs in Q1, 2021. New Found currently has working capital of approximately $67 million.  On closing of the $15 million flow through financing announced March 18, 2021 the Company would have an estimated $82 million of working capital.

Please see the Company’s website at www.newfoundgold.ca and the Company’s SEDAR profile at www.sedar.com.

Acknowledgements

New Found acknowledges the financial support of the Junior Exploration Assistance Program, Department of Natural Resources, Government of Newfoundland and Labrador.

Contact
To contact the Company, please visit the Company’s website, www.newfoundgold.ca and make your request through our investor inquiry form. Our management has a pledge to be in touch with any investor inquiries within 24 hours.

New Found Gold Corp.

Per: “Craig Roberts”
Craig Roberts, P.Eng., Chief Executive Officer
Email: [email protected] 
Phone: (604) 562 9664

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statement Cautions

This press release contains certain “forward-looking statements” within the meaning of Canadian securities legislation, relating to further the exploration and drilling
on the Company’s Queensway gold project in Newfoundland
. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the TSX Venture Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include risks associated possible accidents and other risks associated with mineral exploration operations, the risk that the Company will encounter unanticipated geological factors, the possibility that the Company may not be able to secure permitting and other governmental clearances necessary to carry out the Company’s exploration plans, the risk that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere with the Company’s business and prospects. The reader is urged to refer to the Company’s reports, publicly available through the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com for a more complete discussion of such risk factors and their potential effects.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/keats-infill-drilling-returns-37-2-gt-au-over-6-45m-and-17-9-gt-au-over-8-45m-301257364.html

SOURCE New Found Gold Corp.

Posted on

Great Bear Doubles Vertical Extent of LP Fault, Intersects High-Grade Gold at 942.20 m Downhole: 15.57 g/t Gold Over 3.05 m

PR Newswire

TSX-V:  GBR                                                                             

VANCOUVER, BC, March 29, 2021 /PRNewswire/ – Great Bear Resources Ltd. (the “Company” or “Great Bear”, (TSXV: GBR) (OTCQX: GTBAF) today reported results from its ongoing fully funded $45 million 2021 exploration program at its 100% owned flagship Dixie Project in the Red Lake district of Ontario.


Expansion of the LP Fault

  • Deep drilling has doubled the drill-confirmed vertical extent of the LP Fault gold zone, which begins at bedrock surface, to approximately 800 vertical metres.  The area of ongoing grid drilling extends along 4 kilometres of strike length.  Figure 1 and Figure 2.
  • Three new 400 – 450 metre step-down holes drilled along 500 metres of strike length allsuccessfully intersected the continuation of the LP Fault host rocks and gold mineralization at depths of 700 – 820 vertical metres.
  • Gold grades and mineralized zone thickness were better at depth on two of three tested drill sections.
  • Initial deep drilling tested below the most weakly mineralized segment of the LP Fault, formerly referred to as the “Gap” zone (February 13, 2020).
  • Large scale step-out drilling at depth, including below areas of high-grade gold mineralization, will continue throughout 2021.


High-Grade Gold in the First Deep LP Fault Drill Holes

  • High-grade gold was intersected at depth in two of the three deep drill holes, with better grades and thickness than previously observed in the near surface.  All three deep drill holes contained multiple intervals of gold mineralization.  Table 1 and Table 2.
  • BR-260 is the deepest LP Fault drill hole to date.  It assayed 15.57 g/t gold over 3.05 metres from 942.20 to 945.25 metres, within a broader interval of 1.08 g/t gold over 70.25 metres from 906.15 to 976.40 metres.  Figure 3 and Figure 4.
  • While high-grade intervals are the primary drill targets at these depths, the dual high-grade and bulk-tonnage character of the LP Fault gold zone remains strongly developed at depth.
  • Oriented core data collected from these initial deep holes will assist with determining controls to higher grade panels within the broad envelope of gold mineralization. 

Great Bear has now published results from 270 LP Fault drill holes and anticipates at least 130 additional LP Fault drill holes will be completed by the end of 2021, for a total of at least 400 drill holes.

Chris Taylor, President and CEO of Great Bear said, “We drilled below the most weakly mineralized segment of the LP Fault with our first deep holes, and discovered better gold mineralization at depth.  After 270 drill holes we have yet to find the limits of the LP Fault’s gold mineralization. Mesothermal gold systems of this type, particularly in the Red Lake area, can extend vertically over kilometres.  We are currently working with in-house and external modelers to finalize 2021 drill plans, and will provide guidance over the coming weeks on expected timing of delivery of initial estimates of mineral resources.”

Figure
1
 (Top): Long section of the LP Fault zone showing the locations and depths of the new deep drill holes (labeled). Figure 2 (Bottom) : Map of current drill results showing the location of the new deep drill holes.

Table 1: Drill holes released to date on section 21450 showing increased gold mineralization grades and widths with increasing depth in the former “Gap” zone.  See news releases of April 9, 2020 and May 4, 2020 for previously reported drill holes. New results from BR-260 in italics.


Drill Hole


From (m)


To (m)


Width* (m)


Gold (g/t)


Vertical
Depth (m)

BR-078

176.00

212.90

36.90

0.42

150

BR-097

255.00

259.00

4.00

1.39

220

and

391.70

393.50

1.80

3.49

335

BR-098

419.70

448.50

28.80

0.65

365

and

493.25

495.05

1.80

9.90

425



BR-260



906.15



976.40



70.25



1.08



760



(new)



including



942.20



945.25



3.05



15.57



790


* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time.  Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts.  Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade. 

Table 2: New drill results from the first three deep holes into the LP Fault system along 500 metres of strike length in the “Gap” area.


Drill Hole


From (m)


To (m)


Width* (m)


Gold (g/t)


Section

BR-260


906.15


976.40


70.25


1.08


21450


including


929.30


948.00


18.70


3.33


and including


929.30


929.80


0.50


16.50


and including


942.20


945.25


3.05


15.57


and including


942.20


942.80


0.60


73.10

BR-261

624.85

638.50

13.65

0.57


21200

747.15

761.00

13.85

0.44

811.60

823.25

11.65

0.96


including


822.00


823.25


1.25


5.62

and

835.00

839.50

4.50

1.17

BR-262

871.00

876.50

5.50

1.19


21700


and


933.50


950.50


17.00


1.04


including


946.50


948.50


2.00


7.27


and including


946.50


947.50


1.00


12.30


* Widths are drill indicated core length, as insufficient drilling has been undertaken to determine true widths at this time.  Average grades are calculated with un-capped gold assays, as insufficient drilling has been completed to determine capping levels for higher grade gold intercepts.  Interval widths are calculated using a 0.10 g/t gold cut-off grade with up to 3 m of internal dilution of zero grade. 

Figure
3
: Section 21450 showing BR-260, the deepest drill hole in the LP Fault to date.  This section is located in what was formerly referred to as the “Gap” zone.

Figure 4:  The deepest drill hole in the LP Fault to date.  73.10 g/t gold over 0.60 metres at 942.20 metres down hole in BR-260 (790 metres vertical depth).  The shear-zone hosted disseminated high-grade gold with sparse accessory sulphides within a felsic volcanic host matches mineralization at shallower depths within the LP Fault.  Image is of a selected interval and is not representative of all gold mineralization on the property.

Great Bear’s progress can be followed using the Company’s plan maps, long sections and cross sections, and through the VRIFY model posted at the Company’s web site at www.greatbearresources.ca, which will next be updated in Q2 2021.  All LP Fault drill hole highlighted assays, plus drill collar locations and orientations can also be downloaded at the Company’s web site.

Drill collar location, azimuth and dip for drill holes included in this release are provided in the table below (UTM zone 15N, NAD 83):


Hole ID


Easting


Northing


Elevation


Length


Dip


Azimuth

BR-260

456566

5635016

372

1200

-64

225

BR-261

456714

5634887

364

1284

-63

220

BR-262

456384

5635181

378

1110

-63

224

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

  • High-grade gold in quartz veins and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones). Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes.  These mineralization styles are also typical of the significant mined deposits of the Red Lake district.
  • High-grade disseminated gold with broad moderate to lower grade envelopes (LP Fault).  The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property.  High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals.  The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration.  Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 330 km2 of highly prospective tenure across 5 projects: the flagship Dixie Project (100% owned), the Pakwash Property (earning a 100% interest), the Dedee Property (earning a 100% interest), the Sobel Property (earning a 100% interest), and the Red Lake North Property (earning a 100% interest) all of which are accessible year-round through existing roads.

QA/QC and Core Sampling Protocols

Drill core is logged and sampled in a secure core storage facility located in Red Lake Ontario.  Core samples from the program are cut in half, using a diamond cutting saw, and are sent to Activation Laboratories in Ontario, an accredited mineral analysis laboratory, for analysis. All samples are analysed for gold using standard Fire Assay-AA techniques. Samples returning over 10.0 g/t gold are analysed utilizing standard Fire Assay-Gravimetric methods.  Pulps from approximately 5% of the gold mineralized samples are submitted for check analysis to a second lab.  Selected samples are also chosen for duplicate assay from the coarse reject of the original sample.  Selected samples with visible gold are also analyzed with a standard 1 kg metallic screen fire assay.  Certified gold reference standards, blanks and field duplicates are routinely inserted into the sample stream, as part of Great Bear’s quality control/quality assurance program (QAQC).  No QAQC issues were noted with the results reported herein. 

Qualified Person and NI 43-101 Disclosure

Mr. R. Bob Singh, P.Geo, VP Exploration, and Ms. Andrea Diakow P.Geo, Exploration Manager for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

ON BEHALF OF THE BOARD


“Chris Taylor”                                  

Chris Taylor, President and CEO


Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

Such factors, among other things, include: impacts arising from the global disruption caused by the Covid-19 coronavirus outbreak, business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.

Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/great-bear-doubles-vertical-extent-of-lp-fault-intersects-high-grade-gold-at-942-20-m-downhole-15-57-gt-gold-over-3-05-m-301257347.html

SOURCE Great Bear Resources Ltd.

Posted on

CVS Health to Administer No-Cost COVID-19 Vaccines at Select CVS Pharmacy Locations in Delaware

Delaware is among 44 states where the company is providing access to COVID-19 vaccines

PR Newswire

WOONSOCKET, R.I., March 29, 2021 /PRNewswire/ — In an ongoing effort to expand access to COVID-19 vaccines and help the country move forward from the pandemic, CVS Health (NYSE: CVS) today announced that it will begin vaccinating eligible populations on Wednesday, March 31 at two select CVS Pharmacy locations in Delaware.

The new CVS Pharmacy locations add to several stores already administering the vaccine and continue the company’s retail vaccination efforts in the state that began in February.

For the select retail locations that will begin to offer COVID-19 vaccinations on March 31, appointments will start to become available for booking on Tuesday, March 30, as the store receives shipments of vaccine. Vaccines at participating CVS Pharmacy locations in Delaware will be administered to individuals meeting state criteria, as well as K-12 teachers and staff and childcare workers. Patients must register in advance at CVS.com or through the CVS Pharmacy app, and people without online access can contact CVS customer service: (800) 746-7287. Walk-in vaccinations without an appointment will not be provided.

“We’re proud to play a part in increasing access to the vaccine to as many people as possible to enable reopening efforts in the communities we serve,” said Neela Montgomery, President of CVS Pharmacy and Executive Vice President, CVS Health. “Feedback on every aspect of the vaccination process has been incredibly positive, from the digital experience to interacting with our team of health care professionals whose incredible efforts are helping to move us one step closer towards a healthier post-COVID world.”

There is no cost for the vaccine to patients with insurance or through the federal Health Resources and Services Administration program for uninsured patients.

Participating CVS Pharmacy locations are in Kent and New Castle counties. As more supply becomes available, the company will expand vaccine access through an increasing number of store locations and in more Delaware communities.

The sites in Delaware are among hundreds of CVS Pharmacy locations across 44 states, the District of Columbia, and Puerto Rico where the company is administering COVID-19 vaccine through the Federal Retail Pharmacy Program and, in some cases, with state supply. Vaccines will eventually be administered at CVS Pharmacy locations throughout the country subject to product availability, with the capacity to administer 20 – 25 million shots per month.

Multimedia assets, including b-roll and still photography from long-term care facility and in-store COVID-19 vaccinations, are available here. More information on steps CVS Health has taken to address the pandemic is available at the company’s frequently updated COVID-19 resource center.

About CVS Health
CVS Health is a different kind of health care company. We are a diversified health services company with nearly 300,000 employees united around a common purpose of helping people on their path to better health. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. Built on a foundation of unmatched community presence, our diversified model engages one in three Americans each year. From our innovative new services at HealthHUB® locations, to transformative programs that help manage chronic conditions, we are making health care more accessible, more affordable, and simply better. Learn more about how we’re transforming health at www.cvshealth.com.

Media Contact:

Amy Thibault

401.318.2865
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cvs-health-to-administer-no-cost-covid-19-vaccines-at-select-cvs-pharmacy-locations-in-delaware-301257199.html

SOURCE CVS Health

Posted on

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board

PR Newswire

Dr. Robert C. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory and Deputy Director of the Wu Tsai Neurosciences Institute at Stanford University

NEW YORK, March 29, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has announced the addition of Dr. Robert C. Malenka, an accomplished neuroscientist and psychiatry professor from Stanford University, to Chair the Company’s Scientific Advisory Board. 

Dr. Malenka is an elected member of the National Academy of Sciences and the National Academy of Medicine as well as an elected fellow of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the American College of Neuropsychopharmacology. He has served on the National Advisory Council on Drug Abuse and as a Counselor for the Society for Neuroscience and the American College of Neuropsychopharmacology. He is well known for his landmark contributions to understanding of brain plasticity mechanisms, and has extensive experience as an advisor to various pharmaceutical and biotechnology companies.  

MindMed CEO J.R. Rahn said: “Dr. Malenka has tremendous knowledge and wisdom across several critical fields in which MindMed operates. We are honored to have him join MindMed as Chair of the Scientific Advisory Board. The entire MindMed team is elated to learn and receive guidance from an industry veteran who has guided several pharmaceutical and biotechnology companies throughout their growth and development. As the MindMed team progresses toward achieving MindMed’s goal of providing innovative new potential treatments to the mental health and addiction patient populations, we look forward to Dr. Malenka’s input and guidance.”

Dr. Robert Malenka added: “I am very excited to join the MindMed team and to help bring creative, sophisticated and rigorous scientific approaches to advancing MindMed’s mission of developing new, more efficacious treatments to potentially improve the mental health of the large segments of the population in need. There are incredible opportunities to leverage the use of previously demonized drugs as therapies and combine them with other treatment modalities to potentially achieve more rapid, more effective and longer-lasting reductions in symptoms that often destroy lives and families. New approaches for improving mental health are desperately needed, and I look forward to working with MindMed on such approaches.”

MindMed’s Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development. Such Board leverages decades of deep knowledge in biotechnology and psychiatry to help guide MindMed’s development programs. Members represent institutions such as Johns Hopkins, NYU Langone Health, Duke University, NIH, Stanford University, and Albany Medical College. 


Dr. Robert C. Malenka Bio:

Dr. Robert C. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory and Deputy Director of the Wu Tsai Neurosciences Institute. After graduating from Harvard College he received an M.D. and a Ph.D. in neuroscience in 1983 from Stanford University School of Medicine. Over the ensuing 6 years, he completed residency training in psychiatry at Stanford and 4 years of postdoctoral research at the University of California, San Francisco (UCSF). In 1989, he was appointed Assistant Professor of Psychiatry and Physiology at UCSF, at which he reached the rank of Full Professor in 1996. In addition to running an active research program at UCSF he was the Director of the Center for the Neurobiology of Addiction and Associate Director of the Center for Neurobiology and Psychiatry. He returned to the Stanford University School of Medicine in 1999. He is an elected member of the National Academy of Sciences and the National Academy of Medicine as well as an elected fellow of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the American College of Neuropsychopharmacology. He has served on the National Advisory Council on Drug Abuse and as a Counselor for the Society for Neuroscience and the American College of Neuropsychopharmacology. He is on the scientific advisory boards of numerous non-profit foundations and biotechnology companies. He has been the recipient of numerous awards including: the Society for Neuroscience Young Investigator Award (1993); the Daniel Efron Award from the American College of Neuropsychopharmacolgoy (1998); the Kemali Foundation International Prize in Neuroscience (2000); the CINP-Lilly Neuroscience Basic Research Award (2002), the Perl/UNC Neuroscience Prize (2006), the NARSAD Goldman-Rakic Prize for Outstanding Neuroscience Research (2010), the Pasarow Foundation Award for Extraordinary Accomplishment in Neuropsychiatry Research (2011), and the Society for Neuroscience Julius Axelrod Prize (2016). His laboratory continues to conduct research on the molecular mechanisms of neural plasticity as well as the role of circuit dysfunction in brain disorders including addiction, autism, obsessive compulsive disorder and depression.


About MindMed

MindMed is a psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies. 

MindMed trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States on the OTCQB under the symbol MMEDF, and in Germany under the symbol MMQ. For more information: www.mindmed.co


MindMed Forward-Looking Statements

This press release includes forward-looking statements under applicable securities laws.  Such forward-looking statements involve risks and uncertainties relating to future events, results and the performance of MindMed, and actual events, results and the performance of MindMed may differ materially from these forward-looking statements. Words such as “will,” “may,” “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “potential” and variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include, but are not limited to, statements related to the potential for psychedelic inspired medicines and therapies to achieve more rapid, more effective and longer-lasting reductions in symptoms in the mental health and addiction patient populations. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and progress their preclinical, study and clinical trial programs; the nature, enrollment, timing, results and possible success and therapeutic applications of its products and product candidates and research and preclinical, study and clinical trial programs now underway or planned; and the likelihood, timing, and scope of possible regulatory approval and commercial launch of any product candidates and new indications for any products. Any forward-looking statements are made based on management’s current beliefs and judgment, and MindMed does not undertake any obligation to update publicly any forward-looking statement.s  Investors are cautioned not to rely on these forward-looking statements and are encouraged to read MindMed’s continuous disclosure documents, including, but not limited to, its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com.

Media Contact:

 [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mindmed-announces-the-addition-of-stanford-university-neuroscientist-as-chair-of-the-scientific-advisory-board-301257272.html

SOURCE Mind Medicine (MindMed) Inc.